|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang Z, Huang Y, He H and Ni J:
Podocalyxin promotes cisplatin chemoresistance in osteosarcoma
cells through phosphatidylinositide 3-kinase signaling. Mol Med
Rep. 12:3916–3922. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lippert TH, Ruoff HJ and Volm M: Intrinsic
and acquired drug resistance in malignant tumors. The main reason
for therapeutic failure. Arzneimittelforschung. 58:261–264.
2008.PubMed/NCBI
|
|
4
|
Fletcher JI, Haber M, Henderson MJ and
Norris MD: ABC transporters in cancer: More than just drug efflux
pumps. Nat Rev Cancer. 10:147–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burger H, Loos WJ, Eechoute K, Verweij J,
Mathijssen RH and Wiemer EA: Drug transporters of platinum-based
anticancer agents and their clinical significance. Drug Resist
Updat. 14:22–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li RJ, Zhang GS, Chen YH, Zhu JF, Lu QJ,
Gong FJ and Kuang WY: Down-regulation of mitochondrial ATPase by
hypermethylation mechanism in chronic myeloid leukemia is
associated with multidrug resistance. Ann Oncol. 21:1506–1514.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li SS, Yang S, Wang S, Yang XM, Tang QL
and Wang SH: Latent membrane protein 1 mediates the resistance of
nasopharyngeal carcinoma cells to TRAIL-induced apoptosis by
activation of the PI3K/Akt signaling pathway. Oncol Rep.
26:1573–1579. 2011.PubMed/NCBI
|
|
9
|
Marin JJ, Castaño B, Blazquez AG, Rosales
R, Efferth T and Monte MJ: Strategies for overcoming chemotherapy
resistance in enterohepatic tumours. Curr Mol Med. 10:467–485.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fang Y, Fang D and Hu J: MicroRNA and its
roles in esophageal cancer. Med Sci Monit. 18:RA22–RA30. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sarkar FH, Li Y, Wang Z, Kong D and Ali S:
Implication of microRNAs in drug resistance for designing novel
cancer therapy. Drug Resist Updat. 13:57–66. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shapira A, Livney YD, Broxterman HJ and
Assaraf YG: Nanomedicine for targeted cancer therapy: Towards the
overcoming of drug resistance. Drug Resist Updat. 14:150–163. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hershko DD: Oncogenic properties and
prognostic implications of the ubiquitin ligase Skp2 in cancer.
Cancer. 112:1415–1424. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao M and Karin M: Regulating the
regulators: Control of protein ubiquitinationand ubiquitin-like
modifications by extracellular stimuli. Mol Cell. 19:581–593. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thrower JS, Hoffman L, Rechsteiner M and
Pickart CM: Recognition of the polyubiquitin proteolytic signal.
EMBO J. 19:94–102. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee TY, Chen SA, Hung HY and Ou YY:
Incorporating distant sequence features and radial basis function
networks to identify ubiquitin conjugation sites. PLoS One.
6:e173312011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bielskienė K, Bagdonienė L, Mozūraitienė
J, Kazbarienė B and Janulionis E: E3 ubiquitin ligases as drug
targets and prognostic biomarkers in melanoma. Medicina. 51:1–9.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gong J, Cao J, Liu G and Huo JR: Function
and mechanism of F-box proteins in gastric cancer (Review). Int J
Oncol. 47:43–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao Y and Sun Y: Cullin-RING Ligases as
attractive anti-cancer targets. Curr Pharm Des. 19:3215–3225. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reed SI: Ratchets and clocks: The cell
cycle, ubiquitylation and protein turnover. Nat Rev Mol Cell Biol.
4:855–864. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peters JM: The anaphase promoting
complex/cyclosome: A machine designed to destroy. Nat Rev Mol Cell
Biol. 7:644–656. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kipreos ET and Pagano M: The F-box protein
family. Genome Biol 1: REVIEWS3002, 2000. Epub 2000 Nov 10.
|
|
24
|
Xie CM, Wei W and Sun Y: Role of
SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer.
J Genet Genomics. 40:97–106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Z, Liu P, Inuzuka H and Wei W: Roles
of F-box proteins in cancer. Nat Rev Cancer. 14:233–247. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gong J, Lv L and Huo J: Roles of F-box
proteins in human digestive system tumors (Review). Int J Oncol.
45:2199–2207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gong J and Huo J: New insights into the
mechanism of F-box proteins in colorectal cancer (Review). Oncol
Rep. 33:2113–2120. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hartwell LH, Mortimer RK, Culotti J and
Culotti M: Genetic control of the cell division cycle in yeast: V.
Genetic analysis of cdc mutants. Genetics. 74:267–286.
1973.PubMed/NCBI
|
|
29
|
Akhoondi S, Sun D, von der Lehr N,
Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D,
Marth C, et al: FBXW7/hCDC4 is a general tumor suppressor in human
cancer. Cancer Res. 67:9006–9012. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bedford L, Lowe J, Dick LR, Mayer RJ and
Brownell JE: Ubiquitin-like protein conjugation and the
ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov.
10:29–46. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Minella AC, Welcker M and Clurman BE: Ras
activity regulates cyclin E degradation by the Fbw7 pathway. Proc
Natl Acad Sci USA. 102:9649–9654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yada M, Hatakeyama S, Kamura T, Nishiyama
M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K and
Nakayama KI: Phosphorylation-dependent degradation of c-Myc is
mediated by the F-box protein Fbw7. Embo J. 23:2116–2125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hoeck JD, Jandke A, Blake SM, Nye E,
Spencer-Dene B, Brandner S and Behrens A: Fbw7 controls neural stem
cell differentiation and progenitor apoptosis via Notch and c-Jun.
Nat Neurosci. 13:1365–1372. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rocher-Ros V, Marco S, Mao JH, Gines S,
Metzger D, Chambon P, Balmain A and Saura CA: Presenilin modulates
EGFR signaling and cell transformation by regulating the ubiquitin
ligase Fbw7. Oncogene. 29:2950–2961. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Inuzuka H, Shaik S, Onoyama I, Gao D,
Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al:
SCFFBW7 regulates cellular apoptosis by targeting MCL1
for ubiquitylation and destruction. Nature. 471:104–109. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Inuzuka H, Fukushima H, Shaik S, Liu P,
Lau AW and Wei W: Mcl-1 ubiquitination and destruction. Oncotarget.
2:239–244. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wertz IE, Kusam S, Lam C, Okamoto T,
Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al:
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1
and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tong J, Tan S, Zou F, Yu J and Zhang L:
FBW7 mutations mediate resistance of colorectal cancer to targeted
therapies by blocking Mcl-1 degradation. Oncogene. 36:787–796.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tong J, Wang P, Tan S, Chen D,
Nikolovska-Coleska Z, Zou F, Yu J and Zhang L: Mcl-1 degradation is
required for targeted therapeutics to eradicate colon cancer cells.
Cancer Res. 77:2512–2521. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Song Y, Zhou X, Bai W and Ma X: FBW7
increases drug sensitivity to cisplatin in human nasopharyngeal
carcinoma by downregulating the expression of multidrug
resistance-associated protein. Tumour Biol. 36:4197–4202. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fang L, Yang Z, Zhou J, Tung JY, Hsiao CD,
Wang L, Deng Y, Wang P, Wang J and Lee MH: Circadian clock gene
CRY2 degradation is involved in chemoresistance of colorectal
cancer. Mol Cancer Ther. 14:1476–1487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Thompson BJ, Buonamici S, Sulis ML,
Palomero T, Vilimas T, Basso G, Ferrando A and Aifantis I: The
SCFFBW7 ubiquitin ligase complex as a tumor suppressor
in T cell leukemia. J Exp Med. 204:1825–1835. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
O'Neil J, Grim J, Strack P, Rao S,
Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters
R, et al: FBW7 mutations in leukemic cells mediate NOTCH
pathway activation and resistance to γ-secretase inhibitors. J Exp
Med. 204:1813–1824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ding XQ, Zhao S, Yang L, Zhao X, Zhao GF,
Zhao SP, Li ZJ and Zheng HC: The nucleocytoplasmic translocation
and up-regulation of ING5 protein in breast cancer: A potential
target for gene therapy. Oncotarget. 8:81953–81966. 2017.PubMed/NCBI
|
|
45
|
Yu HG, Wei W, Xia LH, Han WL, Zhao P, Wu
SJ, Li WD and Chen W: FBW7 upregulation enhances cisplatin
cytotoxicity in non-small cell lung cancer cells. Asian Pac J
Cancer Prev. 14:6321–6326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Izumi D, Ishimoto T, Miyake K, Eto T,
Arima K, Kiyozumi Y, Uchihara T, Kurashige J, Iwatsuki M, Baba Y,
et al: Colorectal cancer stem cells acquire chemoresistance through
the upregulation of F-Box/WD repeat-containing protein 7 and the
consequent degradation of c-Myc. Stem Cells. 35:2027–2036. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Takeishi S and Nakayama KI: Role of Fbxw7
in the maintenance of normal stem cells and cancer-initiating
cells. Br J Cancer. 111:1054–1059. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yokobori T, Mimori K, Iwatsuki M, Ishii H,
Onoyama I, Fukagawa T, Kuwano H, Nakayama KI and Mori M:
p53-Altered FBXW7 expression determines poor
prognosis in gastric cancer cases. Cancer Res. 69:3788–3794. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Welcker M, Larimore EA, Frappier L and
Clurman BE: Nucleolar targeting of the fbw7 ubiquitin ligase by a
pseudosubstrate and glycogen synthase kinase 3. Mol Cell Biol.
31:1214–1224. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Balamurugan K, Wang JM, Tsai HH, Sharan S,
Anver M, Leighty R and Sterneck E: The tumour suppressor C/EBPδ
inhibits FBXW7 expression and promotes mammary tumour metastasis.
EMBO J. 29:4106–4117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lerner M, Lundgren J, Akhoondi S, Jahn A,
Ng HF, Moqadam Akbari F, Vrielink Oude JA, Agami R, Den Boer ML,
Grandér D and Sangfelt O: MiRNA-27a controls FBW7/hCDC4-dependent
cyclin E degradation and cell cycle progression. Cell Cycle.
10:2172–2183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xu Y, Sengupta T, Kukreja L and Minella
AC: MicroRNA-223 regulates cyclin E activity by modulating
expression of F-box and WD-40 domain protein 7. J Biol Chem.
285:34439–34446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhou X, Jin W, Jia H, Yan J and Zhang G:
MiR-223 promotes the cisplatin resistance of human gastric cancer
cells via regulating cell cycle by targeting FBXW7. J Exp Clin
Cancer Res. 34:282015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li R, Wu S, Chen X, Xu H, Teng P and Li W:
miR-223/FBW7 axis regulates doxorubicin sensitivity through
epithelial mesenchymal transition in non-small cell lung cancer. Am
J Transl Res. 2016:2512–2524. 2016.
|
|
55
|
Ye M, Zhang Y, Zhang X and Zhang J, Jing
P, Cao L, Li N, Li X, Yao L and Zhang J and Zhang J: Targeting FBW7
as a strategy to overcome resistance to targeted therapy in
non-small cell lung cancer. Cancer Res. 77:3527–3539. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Adua D, Di Fabio F, Ercolani G, Fiorentino
M, Gruppioni E, Altimari A, Limpe Rojas FL, Normanno N, Pinna AD
and Pinto C: Heterogeneity in the colorectal primary tumor and the
synchronous resected liver metastases prior to and after treatment
with an anti-EGFR monoclonal antibody. Mol Clin Oncol. 7:113–120.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zheng M, Xu H, Liao XH, Chen CP, Zhang AL,
Lu W, Wang L, Yang D, Wang J, Liu H, et al: Inhibition of the
prolyl isomerase Pin1 enhances the ability of sorafenib to induce
cell death and inhibit tumor growth in hepatocellular carcinoma.
Oncotarget. 8:29771–29784. 2017.PubMed/NCBI
|
|
58
|
Lupini L, Bassi C, Mlcochova J, Musa G,
Russo M, Vychytilova-Faltejskova P, Svoboda M, Sabbioni S, Nemecek
R, Slaby O and Negrini M: Prediction of response to anti-EGFR
antibody-based therapies by multigene sequencing in colorectal
cancer patients. BMC Cancer. 15:8082015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Eto K, Iwatsuki M, Watanabe M, Ishimoto T,
Ida S, Imamura Y, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, et al:
The sensitivity of gastric cancer to trastuzumab is regulated by
the miR-223/FBXW7 pathway. Int J Cancer. 136:1537–1545. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Demetrick DJ, Zhang H and Beach DH:
Chromosomal mapping of the genes for the human CDK2/cyclin
A-associated proteins p19 (SKP1A and SKP1B) and p45 (SKP2).
Cytogenet Cell Genet. 73:104–107. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hershko D, Bornstein G, Ben-Izhak O,
Carrano A, Pagano M, Krausz MM and Hershko A: Inverse relation
between levels of p27Kip1 and of its ubiquitin ligase
subunit Skp2 in colorectal carcinomas. Cancer. 91:1745–1751. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Fukuchi M, Masuda N, Nakajima M, Fukai Y,
Miyazaki T, Kato H and Kuwano H: Inverse correlation between
expression levels of p27 and the ubiquitin ligase subunit Skp2 in
early esophageal squamous cell carcinoma. Anticancer Res.
24:777–783. 2004.PubMed/NCBI
|
|
63
|
Yang G, Ayala G and De Marzo A: Tian W,
Frolov A, Wheeler TM, Thompson TC and Harper JW: Elevated Skp2
protein expression in human prostate cancer: Association with loss
of the cyclin-dependent kinase inhibitor p27 and PTEN and with
reduced recurrence-free survival. Clin Cancer Res. 8:3419–3426.
2002.PubMed/NCBI
|
|
64
|
Traub F, Mengel M, Lück HJ, Kreipe HH and
von Wasielewski R: Prognostic impact of Skp2 and p27 in human
breast cancer. Breast Cancer Res Treat. 99:185–191. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Rose AE, Wang G, Hanniford D, Monni S, Tu
T, Shapiro RL, Berman RS, Pavlick AC, Pagano M, Darvishian F, et
al: Clinical relevance of SKP2 alterations in metastatic melanoma.
Pigment Cell Melanoma Res. 24:197–206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Xu HM, Liang Y, Chen Q, Wu QN, Guo YM,
Shen GP, Zhang RH, He ZW, Zeng YX, Xie FY, et al: Correlation of
Skp2 overexpression to prognosis of patients with nasopharyngeal
carcinoma from South China. Chin J Cancer. 30:204–212. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Schüler S, Diersch S, Hamacher R, Schmid
RM, Saur D and Schneider G: SKP2 confers resistance of pancreatic
cancer cells towards TRAIL induced apoptosis. Int J Oncol.
38:219–225. 2011.PubMed/NCBI
|
|
68
|
Wang Z, Fukushima H, Inuzuka H, Wan L, Liu
P, Gao D, Sarkar FH and Wei W: Skp2 is a promising therapeutic
target in breast cancer. Front Oncol. 1:pii: 18702. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Shapira M, Ben-Izhak O, Linn S, Futerman
B, Minkov I and Hershko DD: The prognostic impact of the ubiquitin
ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer.
103:1336–1346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Blagosklonny MV: Review Why therapeutic
response may not prolong the life of a cancer patient: Selection
for oncogenic resistance. Cell Cycle. 4:1693–1698. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhuang K, Zhang L, Zhang X, Tang H, Zhang
J, Yan Y, Han K and Guo H: Gastrin induces multidrug resistance via
the degradation of p27Kip1 in the gastric carcinoma cell
line SGC7901. Int J Oncol. 50:2091–2100. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Huang T, Yang L, Wang G, Ding G, Peng B,
Wen Y and Wang Z: Inhibition of Skp2 sensitizes lung cancer cells
to paclitaxel. Onco Targets Ther. 10:439–446. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Davidovich S, Ben-Izhak O, Shapira M,
Futerman B and Hershko DD: Over-expression of Skp2 is associated
with resistance to preoperative doxorubicin-based chemotherapy in
primary breast cancer. Breast Cancer Res. 10:R632008. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Schüler S, Diersch S, Hamacher R, Schmid
RM, Saur D and Schneider G: SKP2 confers resistance of pancreatic
cancer cells towards TRAIL-induced apoptosis. Int J Oncol.
38:219–225. 2011.PubMed/NCBI
|
|
75
|
Totary-Jain H, Sanoudou D, Dautriche CN,
Schneller H, Zambrana L and Marks AR: Rapamycin resistance is
linked to defective regulation of Skp2. Cancer Res. 72:1836–1843.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Chan CH, Li CF, Yang WL, Gao Y, Lee SW,
Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, et al: The Skp2-SCF
E3 ligase regulates Akt ubiquitination, glycolysis, herceptin
sensitivity, and tumorigenesis. Cell. 149:1098–1111. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Wang J, Han F, Wu J, Lee SW, Chan CH, Wu
CY, Yang WL, Gao Y, Zhang X, Jeong YS, et al: The role of Skp2 in
hematopoietic stem cell quiescence, pool size, and self-renewal.
Blood. 118:5429–5438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Guardavaccaro D, Kudo Y, Boulaire J,
Barchi M, Busino L, Donzelli M, Margottin-Goguet F, Jackson PK,
Yamasaki L and Pagano M: Control of meiotic and mitotic progression
by the F box protein beta-Trcp1 in vivo. Dev Cell. 4:799–812. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Müerköster S, Arlt A, Sipos B, Witt M,
Grossmann M, Klöppel G, Kalthoff H, Fölsch UR and Schäfer H:
Increased expression of the E3-ubiquitin ligase receptor subunit
betaTRCP1 relates to constitutive nuclear factor-kappaB activation
and chemoresistance in pancreatic carcinoma cells. Cancer Res.
65:1316–1324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Pan Y, Zhang F, Zhao Y, Shao D, Zheng X,
Chen Y, He K, Li J and Chen L: Berberine enhances chemosensitivity
and induces apoptosis through dose-orchestrated AMPK signaling in
breast cancer. J Cancer. 8:1679–1689. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wang N, Wang X, Tan HY, Li S, Tsang CM,
Tsao SW and Feng Y: Berberine suppresses cyclin D1 expression
through proteasomal degradation in human hepatoma cells. Int J Mol
Sci. 17:pii: E1899. 2016. View Article : Google Scholar
|
|
82
|
Harder B, Jiang T, Wu T, Tao S, de la Vega
Rojo M, Tian W, Chapman E and Zhang DD: Molecular mechanisms of
Nrf2 regulation and how these influence chemical modulation for
disease intervention. Biochem Soc Trans. 43:680–686. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chowdhry S, Zhang Y, McMahon M, Sutherland
C, Cuadrado A and Hayes JD: Nrf2 is controlled by two distinct
β-TrCP recognition motifs in its Neh6 domain, one of which can be
modulated by GSK-3 activity. Oncogene. 32:3765–3781. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Woo Y, Oh J and Kim JS: Suppression of
Nrf2 activity by chestnut leaf extract increases chemosensitivity
of breast cancer stem cells to paclitaxel. Nutrients. 9:pii: E760.
2017. View Article : Google Scholar
|
|
85
|
Karathedath S, Rajamani BM, Aalam Musheer
SM, Abraham A, Varatharajan S, Krishnamurthy P, Mathews V,
Velayudhan SR and Balasubramanian P: Role of NF-E2 related factor 2
(Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML)
and the effect of pharmacological inhibition of Nrf2. PLoS One.
12:e01772272017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Duong HQ, You KS, Oh S, Kwak SJ and Seong
YS: Silencing of NRF2 reduces the expression of ALDH1A1 and ALDH3A1
and sensitizes to 5-FU in pancreatic cancer cells. Antioxidants.
6:pii: E52. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Chang KY, Hsu TI, Hsu CC, Tsai SY, Liu JJ,
Chou SW, Liu MS, Liou JP, Ko CY, Chen KY, et al: Specificity
protein 1-modulated superoxide dismutase 2 enhances temozolomide
resistance in glioblastoma, which is independent of
O6-methylguanine-DNA methyltransferase. Redox Biol.
13:655–664. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Liu WH and Chang LS: Fas/FasL-dependent
and -independent activation of caspase-8 in doxorubicin-treated
human breast cancer MCF-7 cells: ADAM10 down-regulation activates
Fas/FasL signaling pathway. Int J Biochem Cell Biol. 43:1708–1719.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Wu WD, Wang M, Ding HH and Qiu ZJ: FBXL5
attenuates RhoGDI2-induced cisplatin resistance in gastric cancer
cells. Eur Rev Med Pharmacol Sci. 20:2551–2557. 2016.PubMed/NCBI
|
|
90
|
Cho HJ, Baek KE, Park SM, Kim IK, Nam IK,
Choi YL, Park SH, Im MJ, Choi J, Ryu J, et al: RhoGDI2 confers
gastric cancer cells resistance against cisplatin-induced apoptosis
by upregulation of Bcl-2 expression. Cancer Lett. 311:48–56. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Wang X, Pankratz VS, Fredericksen Z,
Tarrell R, Karaus M, McGuffog L, Pharaoh PD, Ponder BA, Dunning AM,
Peock S, et al: Common variants associated with breast cancer in
genome-wide association studies are modifiers of breast cancer risk
in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 19:2886–2897.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Coon TA, Glasser JR, Mallampalli RK and
Chen BB: Novel E3 ligase component FBXL7 ubiquitinates and degrades
Aurora A, causing mitotic arrest. Cell Cycle. 11:721–729. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Liu Y, Lear T, Iannone O, Shiva S, Corey
C, Rajbhandari S, Jerome J, Chen BB and Mallampalli RK: The
proapoptotic F-box protein Fbxl7 regulates mitochondrial function
by mediating the ubiquitylation and proteasomal degradation of
survivin. J Biol Chem. 290:11843–11852. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Kamran M, Long ZJ, Xu D, Lv SS, Liu B,
Wang CL, Xu J, Lam EW and Liu Q: Aurora kinase A regulates Survivin
stability through targeting FBXL7 in gastric cancer drug resistance
and prognosis. Oncogenesis. 6:e2982017. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lehman NL, Tibshirani R, Hsu JY, Natkunam
Y, Harris BT, West RB, Masek MA, Montgomery K, van de Rijn M and
Jackson PK: Oncogenic regulators and substrates of the anaphase
promoting complex/cyclosome are frequently overexpressed in
malignant tumors. Am J Pathol. 170:1793–1805. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Gütgemann I, Lehman NL, Jackson PK and
Longacre TA: Emi1 protein accumulation implicates misregulation of
the anaphase promoting complex/cyclosome pathway in ovarian clear
cell carcinoma. Mod Pathol. 21:445–454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Shimizu N, Nakajima N, Tsunematsu T, Ogawa
I, Kawai H, Hirayama R, Fujimori A, Yamada A, Okayasu R, Ishimaru
N, et al: Selective enhancing effect of early mitotic inhibitor 1
(Emi1) depletion on the sensitivity of doxorubicin or X-ray
treatment in human cancer cells. J Biol Chem. 288:17238–17252.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Zhang YW, Brognard J, Coughlin C, You Z,
Dolled-Filhart M, Aslanian A, Manning G, Abraham RT and Hunter T:
The F box protein Fbx6 regulates Chk1 stability and cellular
sensitivity to replication stress. Mol Cell. 35:442–453. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Katayama K, Noguchi K and Sugimoto Y:
FBXO15 regulates P-glycoprotein/ABCB1 expression through the
ubiquitin-proteasome pathway in cancer cells. Cancer Sci.
104:694–702. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ravindranath AK, Kaur S, Wernyj RP,
Kumaran MN, Miletti-Gonzalez KE, Chan R, Lim E, Madura K and
Rodriguez-Rodriguez L: CD44 promotes multi-drug resistance by
protecting P-glycoprotein from FBXO21-mediated ubiquitination.
Oncotarget. 6:26308–26321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Wu B, Liu ZY, Cui J, Yang XM, Jing L, Zhou
Y, Chen ZN and Jiang JL: F-box protein FBXO22 mediates
polyubiquitination and degradation of CD147 to reverse cisplatin
resistance of tumor cells. Int J Mol Sci. 18:pii: E212. 2017.
View Article : Google Scholar
|
|
102
|
Hanai J, Cao P, Tanksale P, Imamura S,
Koshimizu E, Zhao J, Kishi S, Yamashita M, Phillips PS, Sukhatme VP
and Lecker SH: The muscle-specific ubiquitin ligase atrogin-1/MAFbx
mediates statin-induced muscle toxicity. J Clin Invest.
117:3940–3951. 2007.PubMed/NCBI
|
|
103
|
Tanaka N, Kosaka T, Miyazaki Y, Mikami S,
Niwa N, Otsuka Y, Minamishima YA, Mizuno R, Kikuchi E, Miyajima A,
et al: Acquired platinum resistance involves epithelial to
mesenchymal transition through ubiquitin ligase FBXO32
dysregulation. JCI Insight. 1:e836542016. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Tan J, Yang X, Zhuang L, Jiang X, Chen W,
Lee PL, Karuturi RK, Tan PB, Liu ET and Yu Q: Pharmacologic
disruption of Polycomb-repressive complex 2-mediated gene
repression selectively induces apoptosis in cancer cells. Genes
Dev. 21:1050–1063. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Lorenzi F, Babaei-Jadidi R, Sheard J,
Spencer-Dene B and Nateri AS: Fbxw7-associated drug resistance is
reversed by induction of terminal differentiation in murine
intestinal organoid culture. Mol Ther Methods Clin Dev.
3:160242016. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhang X, Kong Y, Xu X, Xing H, Zhang Y,
Han F, Li W, Yang Q, Zeng J, Jia J and Lui Z: F-box protein FBXO31
is down-regulated in gastric cancer and negatively regulated by
miR-17 and miR-20a. Oncotarget. 5:6178–6190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Huang HL, Zheng WL, Zhao R, Zhang B and Ma
WL: FBXO31 is down-regulated and may function as a tumor suppressor
in hepatocellular carcinoma. Oncol Rep. 24:715–720. 2010.PubMed/NCBI
|
|
108
|
Liu J, Lv L, Gong J, Tan Y, Zhu Y, Dai Y,
Pan X, Huen MS, Li B, Tsao SW, et al: Overexpression of F-box only
protein 31 predicts poor prognosis and deregulates p38α- and
JNK-mediated apoptosis in esophageal squamous cell carcinoma. Int J
Cancer. 142:145–155. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Kogo R, Mimori K, Tanaka F, Komune S and
Mori M: FBXO31 determines poor prognosis in esophageal squamous
cell carcinoma. Int J Oncol. 39:155–159. 2011.PubMed/NCBI
|
|
110
|
Guerrero-Garcia TA, Mogollon RJ and
Castillo JJ: Bortezomib in plasmablastic lymphoma: A glimpse of
hope for a hard-to-treat disease. Leuk Res. 62:12–16. 2017.
View Article : Google Scholar : PubMed/NCBI
|
